Key Statistics
~20
ADCs approved globally
FDA · EMA · PMDA
200+
Candidates in clinical development
Phase I through Phase III
$3.75B
Enhertu partner sales, 2024
Highest-selling ADC globally
$43B
Largest ADC acquisition
Pfizer – Seagen, 2023
$28–35B
Forecast market size 2035
Across published analyst models
~11%
ADC CDMO market CAGR
$8.9B (2024) → $16.6B (2030)
Target Profile
| Report Code | ARP-ADC-2026-06June 2026 |
|---|---|
| Category | Competitive Intelligence · Market Analysis · Supply Chain |
| Platforms | BIO 360HEORviaNexigen |
| Scope | ~20 approved ADCs · 200+ clinical candidates · 6 landmark deals ($2B–$43B) · ADC CDMO market · HEOR & HTA landscape · 2035 market forecast |
| Key Indications | Breast Cancer (HER2+, HER2-low)Urothelial CancerNSCLCOvarian CancerHematologic Malignancies |
| Methodology | Public analyst and company sources (Roots Analysis, Grand View Research, Technavio, Towards Healthcare) · Company disclosures (Pfizer, AstraZeneca, Daiichi Sankyo, Gilead, AbbVie, Merck, GSK) · FDA/EMA regulatory databases · Not investment advice |
Report Overview
ADC Market, Competitive & Supply-Chain Intelligence
400+Preclinical
110+Phase I
70+Phase II
30+Phase III
3NDA / MAA
~20Approved
Approved ADC Landscape
Pipeline by Development Stage
Approved ADCs · Selected Disclosed Assets
| Product (INN) | Target | Company | Approved | Lead Indication | Payload Class |
| Adcetris | CD30 | Pfizer / Takeda | 2011 | Hodgkin lymphoma | Auristatin (MMAE) |
| Kadcyla | HER2 | Roche | 2013 | HER2+ breast cancer | Maytansinoid (DM1) |
| Padcev | Nectin-4 | Astellas / Pfizer | 2019 | Urothelial cancer | Auristatin (MMAE) |
| Enhertu ★ | HER2 | Daiichi Sankyo / AZ | 2019 | HER2+ / HER2-low breast, gastric, NSCLC | Topo-I (deruxtecan) |
| 🔒 Approved ADC 5 | — | Major Pharma | Locked | Details in full report | — |
| 🔒 Approved ADC 6 | — | Major Pharma | Locked | Details in full report | — |
| 14+ more approved, 200+ pipeline assets... | Multiple | Various | All stages | Full details in paid report | — |
Drug Landscape
| Drug Name | Company | Modality | Indication | Stage | Mechanism |
| Adcetris | Pfizer / Takeda | ADC (Auristatin MMAE) | Hodgkin Lymphoma (CD30) | Approved 2011 | Anti-CD30 antibody-drug conjugate linked to an MMAE payload |
| Kadcyla | Roche | ADC (Maytansinoid DM1) | HER2+ Breast Cancer | Approved 2013 | Anti-HER2 antibody-drug conjugate linked to a DM1 payload |
| Padcev | Astellas / Pfizer | ADC (Auristatin MMAE) | Urothelial Cancer (Nectin-4) | Approved 2019 | Anti-Nectin-4 antibody-drug conjugate linked to an MMAE payload |
| Enhertu ★ | Daiichi Sankyo / AstraZeneca | ADC (Topoisomerase-1 Inhibitor) | HER2+ / HER2-low Breast, Gastric, NSCLC | Approved 2019 | Anti-HER2 antibody-drug conjugate linked to a deruxtecan payload |
| 🔒 Approved ADC 5 | Major Pharma | — | Locked | Approved | Details in full report |
| 🔒 Approved ADC 6 | Major Pharma | — | Locked | Approved | Details in full report |
| 14+ more approved, 200+ pipeline assets... | Multiple | — | Various | All stages | Full details in paid report |
#ADC#AntibodyDrugConjugates#Oncology#Enhertu#HER2#TROP2#BioPharma#DrugDiscovery#ClinicalTrials#PrecisionMedicine#TargetedTherapy#CompetitiveIntelligence#CDMO#AripaResearch